AVITA Medical Upgraded to Neutral by BTIG: 88.51% Upside Potential

BTIG upgraded AVITA Medical (RCEL) from Sell to Neutral, with an average one-year price target of $7.45/share, representing an 88.51% increase from its latest closing price of $3.95/share. The projected annual revenue is 59MM, a decrease of 18.73%, and the projected annual non-GAAP EPS is -1.22. Institutional ownership has increased by 0.58% to 6,630K shares, with a put/call ratio of 0.15 indicating a bullish outlook.